BRPI0716815A2 - HETEROATOMATIC POST HAVING AGONIST AND / OR ANTAGONIST BIOLOGICAL ACTIVITY OF SPINPHOSINE-1-PHOSPHATE (S1P) RECEIVER - Google Patents
HETEROATOMATIC POST HAVING AGONIST AND / OR ANTAGONIST BIOLOGICAL ACTIVITY OF SPINPHOSINE-1-PHOSPHATE (S1P) RECEIVERInfo
- Publication number
- BRPI0716815A2 BRPI0716815A2 BRPI0716815-2A2A BRPI0716815A BRPI0716815A2 BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2 BR PI0716815 A BRPI0716815 A BR PI0716815A BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2
- Authority
- BR
- Brazil
- Prior art keywords
- spinphosine
- heteroatomatic
- agonist
- phosphate
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82480706P | 2006-09-07 | 2006-09-07 | |
PCT/US2007/077588 WO2008030843A1 (en) | 2006-09-07 | 2007-09-05 | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0716815A2 true BRPI0716815A2 (en) | 2013-11-05 |
Family
ID=38961939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0716815-2A2A BRPI0716815A2 (en) | 2006-09-07 | 2007-09-05 | HETEROATOMATIC POST HAVING AGONIST AND / OR ANTAGONIST BIOLOGICAL ACTIVITY OF SPINPHOSINE-1-PHOSPHATE (S1P) RECEIVER |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2066633A1 (en) |
JP (1) | JP2010504286A (en) |
AU (1) | AU2007292347A1 (en) |
BR (1) | BRPI0716815A2 (en) |
CA (1) | CA2662852A1 (en) |
WO (1) | WO2008030843A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005014271A1 (en) * | 2005-03-24 | 2006-09-28 | Rhein Chemie Rheinau Gmbh | Microgels in combination with functional additives |
WO2008141013A1 (en) * | 2007-05-08 | 2008-11-20 | Allergan, Inc. | S1p3 receptor inhibitors for treating pain |
HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
SI2342205T1 (en) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
CA2780908A1 (en) | 2009-11-24 | 2011-06-03 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
ES2937386T3 (en) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts of same |
WO2011109471A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
US8513220B2 (en) | 2010-05-14 | 2013-08-20 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity |
US20110281822A1 (en) | 2010-05-14 | 2011-11-17 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
ES2548258T3 (en) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Oxadiazole compounds substituted and their use as S1P1 agonists |
EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP6838744B2 (en) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1) |
CN110545848A (en) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | Compounds and methods for treating inflammatory bowel disease with extra-intestinal manifestations |
KR20190116416A (en) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | Compounds and Methods for Treating Primary Bile Cholangitis |
WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665159B1 (en) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1992002513A1 (en) * | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
JP4773972B2 (en) * | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | (3,4-Disubstituted) propanecarboxylic acids as S1P (Edg) receptor agonists |
-
2007
- 2007-09-05 BR BRPI0716815-2A2A patent/BRPI0716815A2/en not_active IP Right Cessation
- 2007-09-05 JP JP2009527532A patent/JP2010504286A/en active Pending
- 2007-09-05 AU AU2007292347A patent/AU2007292347A1/en not_active Abandoned
- 2007-09-05 CA CA002662852A patent/CA2662852A1/en not_active Abandoned
- 2007-09-05 WO PCT/US2007/077588 patent/WO2008030843A1/en active Application Filing
- 2007-09-05 EP EP07841853A patent/EP2066633A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2066633A1 (en) | 2009-06-10 |
CA2662852A1 (en) | 2008-03-13 |
JP2010504286A (en) | 2010-02-12 |
WO2008030843A1 (en) | 2008-03-13 |
AU2007292347A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0716815A2 (en) | HETEROATOMATIC POST HAVING AGONIST AND / OR ANTAGONIST BIOLOGICAL ACTIVITY OF SPINPHOSINE-1-PHOSPHATE (S1P) RECEIVER | |
LTPA2021502I1 (en) | Pharmaceutical combinations of angiotensin receptor antagonist and NEP inhibitor | |
BRPI0813580A2 (en) | NON-BASIC MELANINE CONCENTRATION HORMONE RECEPTOR 1 ANTAGONISTS AND METHODS | |
BRPI0815668A2 (en) | pyrrol compounds having sphingosine-1-phosphate receptor antagonist and agonist biological activity. | |
BRPI1014877A8 (en) | diamide compounds having muscarinic receptor antagonist and adrenergic b2 receptor agonist activity. | |
BRPI0720124A2 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE. | |
DK1615889T3 (en) | Biphenyl derivatives with beta2-adrenergic receptor agonist and muscarinic receptor antagonist activity | |
DE602004018575D1 (en) | Surgical ultrasound system and sample | |
BRPI0808001A2 (en) | ANALYZED MONITORING DEVICE COVERED WITH POLYMER CONTAINING HETEROCYCLIC NITROGEN AND METHODS OF USE. | |
EP1848999A4 (en) | Fecal sample test device and methods of use | |
EP2089391A4 (en) | Bruton's tyrosine kinase activity probe and method of using | |
ECSP088872A (en) | ANTAGONISTS OF SUBSTITUTED MONOCYCLIC RECEIVERS CGRP | |
BRPI0919539A2 (en) | peripheral opioid receptor antagonists and their uses | |
ATE420088T1 (en) | QUINOLINONECARBONIC ACID AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | |
MA29557B1 (en) | PREPARATIONS OF ERYTHROPOIETIN RECEPTOR AGONIST PEPTIDES AND USES THEREOF | |
BRPI0716732A2 (en) | gnss signal acquisition system and / or method | |
EP1789788A4 (en) | Immobilized probes and methods of detecting conformationally altered prion proteins | |
DE602005009355D1 (en) | DISABLED HIMBACINANALOGA AS THROMBIN RECEPTOR ANTAGONISTS | |
BRPI0806966A2 (en) | COMBINATION OF A MUSCARINE RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | |
BRPI0810606A2 (en) | IMPLANT DEVICE DEVICE AGENTS AND METHODS OF USE | |
BRPI0719776A2 (en) | WATER LIQUID PREPARATION HAVING IMPROVED INTRAOCULAR GATIFLOXACIN PENETRATION | |
ITTO20040743A1 (en) | DISPOSABLE HOMOGENIZING DEVICE, AND ITS USE FOR THE PREPARATION OF HOMOGENIZED SAMPLES | |
DE602005015858D1 (en) | ULTRASOUND PROBE | |
ITRM20060176A1 (en) | PROCEDURE FOR MULTIMEDIA ANALYSIS AND MONITORING OF REHABILITATION ACTIVITIES AND MEANS FOR ITS IMPLEMENTATION | |
BRPI0619980A2 (en) | FTAMALIDE AND ANILINE DERIVATIVES, AGRICULTURAL OR HORTICULIC INSECTICIDE, AND METHOD OF USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08L | Application fees: final archiving |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES. |
|
B08I | Application fees: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |